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Abstract
Background: Thyroglobulin (Tg) measurement fol-
lowing thyrotropin (TSH) stimulation is used in the
follow-up of patients with differentiated thyroid car-
cinoma (DTC). However, high-sensitive assays allow
accurate measurement of serum Tg even without TSH
stimulation. Here, we prospectively evaluated the
impact of unstimulated high-sensitive Tg measure-
ment in early and long-term outcome of patients with
DTC.
Methods: One hundred and ninety five patients affect-
ed with DTC were evaluated. Six months after thyroid
ablation (i.e., thyroidectomy plus radioiodine) serum
Tg was measured during TSH-suppressive thyroxine
(T4) treatment (onT4-Tg). Patients with undetectable
onT4-Tg and negative neck ultrasound (US) were
considered disease free and onT4-Tg was measured
every 12 months for a mean follow-up of 6.8 (4.7–8.9)
years. Patients with an increase in onT4-Tg under-
went specific diagnostic work-up and appropriate
treatment if necessary.
Results: Four patients showed recurrence at first
follow-up visit with a corresponding increase in onT4-
Tg concentrations (sensitivity 100%). Three patients
had false positive onT4-Tg measurement (specificity
98%) with a spontaneous decrease within 3–6 months
in all cases (specificity 100%). Three of 188 patients
with undetectable serum onT4-Tg at first follow-up
showed recurrence later with an increase in onT4-Tg
as the first (ns2) or unique (ns1) sign of relapse
(sensitivity 100%). Among 185 disease-free patients in
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a prolonged follow-up, 12 had a transient increase in
onT4-Tg (specificity 91.6%). However, a spontaneous
reduction within 3–6 months occurred in all cases
(specificity 100%).
Conclusions: Undetectable serum onT4-Tg using a
high-sensitivity immunoradiometric assay 6 months
after thyroid ablation predicts low-risk of DTC recur-
rence. When onT4-Tg became detectable during
follow-up, the evaluation of Tg slope in a 3–6 months
period accurately discriminated patients with DTC
recurrence from those without recurrence. This
helped avoid unnecessary diagnostic or therapeutic
procedures.
Clin Chem Lab Med 2009;47:1001–4.
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Introduction
Thyroglobulin (Tg) measurement following thyro-
tropin (TSH) stimulation is a useful tool in the man-
agement of patients affected by differentiated thyroid
carcinoma (DTC) treated by thyroid ablation (i.e., thy-
roidectomy and radioiodine) (1, 2). Recently, Tg meas-
urement during thyroxine (T4) treatment using
high-sensitive assays (onT4-Tg) proved to be effec-
tive, even without TSH stimulation (3, 4). Using a
high-sensitive immunoradiometric Tg assay, we pre-
viously found a 96% negative predictive value among
patients undergoing T4 treatment. A further increase
to 99% was obtained by coupling onT4-Tg and neck
ultrasonography (US) (5). Globally, as confirmed even
by using different high-sensitive Tg assays, few
patients with undetectable onT4-Tg had a pathologi-
cal Tg response (i.e., )2 ng/mL) to recombinant
human TSH (rhTSH) stimulation, and less actually
recurred (6, 7). Otherwise, no prospective data are
available (8). The present study was undertaken to
evaluate the impact of onT4-Tg measurement on both
early and long-term outcome of patients with DTC.
Materials and methods
Patients
We enrolled 231 of 288 patients with histologically proven
DTC wmean (SD) age, 52 (18) years; 24% malex papillary: 197,
follicular: 34 with a low-risk profile according to European
Thyroid Association Guidelines (2). Excluded were patients
with 1. aggressive histotypes (i.e., papillary: tall-cell, colum-
nar-cell, diffuse sclerosing; follicular: Hurtle-cell, widely inva-
sive or poorly differentiated) (ns9); 2. maximum tumor
diameter more than 40 mm and/or lymph-node(s) involve
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Figure 1 Follow-up and outcome of 195 patients with low-risk of DTC.
ment (N1) (ns39); 3. distant metastases (M1) (ns9). All
patients were treated with total thyroidectomy and
131I-iodide (3700 MBq) administration. Those with positive
anti-thyroglobulin antibodies (TgAb) (ns33) and/or undetec-
table Tg before radioiodine ablation (ns3) were also exclud-
ed. After radioiodine ablation T4 was administered to
suppress TSH (target -0.1 mUI/L with normal fT3) and the
first follow-up visit 6 months later was characterized by neck
US and serum TSH, Tg and TgAb measurements. Patients
having detectable onT4-Tg (i.e., G0.2 ng/mL, see below) and/
or positive US were further evaluated with US-guided fine-
needle cytology (FNC) and/or other imaging procedures wi.e.,
18FDG-positron emission tomography/computed tomogra-
phy (PET/CT), magnetic resonance imaging (MRI), PT-WBSx.
If multi-imaging procedures tested negative, onT4-Tg was
measured every 3 months and the Tg trend evaluated.
Recurrences were confirmed by cytology, histology or spe-
cific radioiodine uptake. Patients with undetectable onT4-Tg
and negative US were considered cured, T4 titred to obtain
a TSH level from 0.1 mUI/L to 0.5 mUI/L and further visits,
with neck US and TSH, Tg and TgAb measurements, per-
formed every 12 months over an average of 6.8 (4.7–8.9)
years of follow-up. Patients had ‘‘no evidence of disease’’ if
no lesions were detected during follow-up (or Tg spontane-
ously normalized without treatment). Patients had ‘‘disease
recurrence’’ when recurrences were proven histologically or
lesions disappeared after specific radioiodine treatment.
Finally, patients had ‘‘biochemical recurrence’’ if Tg
increased progressively without any detectable lesion in
multi-imaging procedures wincluding post-treatment whole
body scan (PT-WBS)x.
Methods
Tg measurement Serum Tg was assayed in duplicate using
a specific IRMA assay (DYNOtest Tg-plus, BRAHMS Dia-
gnostica GmbH, Berlin, Germany) according to the manufac-
turer’s instructions and our previously published reports
(5, 9). Standardization of the assay is based on the interna-
tional standard certified reference material (CRM) 457. One
ng in the DYNOtest Tg-plus is equivalent to 2 ng of CRM.
Quality control consisted of measurement of two levels of
control sera in each series. We reanalyzed showing a coef-
ficient of variation exceeding 10% and participated bimonth-
ly in the European interlaboratory control Oncocheck. This
method showed a functional sensitivity of 0.2 ng/mL; con-
sequently serum Tg concentrations -0.2 ng/mL were report-
ed as undetectable (9, 10).
Screening for interferences The presence of anti-thyro-
globulin antibodies (TgAb) was assessed using a specific
radioimmunoassay (DYNOtest anti-TGn, BRAHMS Dia-
gnostica GmbH, Berlin, Germany) and a recovery test per-
formed using buffer provided by the manufacturer with a
cut-off value of 80%. Samples with TgAb)60 UI/mL and/or
recovery -80% were excluded. All samples were retested
after incubation in heterophile-blocking tubes (HBT; Scanti-
bodies, Santee, CA, USA) at room temperature for 1 h. Samples
with Tg falling to -30% of their original value, becoming
undetectable or increasing more than 30% of their original
value were considered as having interference and excluded.
TSH and fT3 assay Serum TSH and fT3 concentrations
were measured using immunochemiluminometric assays on
the Immulite 2000 platform (Diagnostic Products Corpora-
tion, Los Angeles, CA, USA).
Results
As shown in Figure 1, seven of 195 (3.5%) patients
had detectable onT4-Tg (from 0.3 ng/mL to 1.4 ng/mL)
with a corresponding suppressed TSH (i.e., -0.1
mUI/L) at the first follow-up visit; two had neck lymph
node metastases (onT4-Tg 0.6 and 1.1 ng/mL, respec-
tively), one recurred in the thyroid bed (onT4-Tg
0.5 ng/mL) and one in a mediastinal lymph node
(onT4-Tg 1.4 ng/mL). Lesions were histologically con-
firmed (ns3) or resolved after radioiodine treatment
(ns1). A spontaneous reduction in onT4-Tg from 0.3,
0.5 and 0.8 ng/mL to undetectable concentrations
occurred in three patients over a 3–6 months period;
none of these relapsed in 3.7–7.1 years of follow-up.
Two of 188 (1%) patients with undetectable onT4-Tg
at first visit showed recurrence during long-term fol-
low-up. In the first patient, serum onT4-Tg became
detectable 9 months following thyroid ablation
(0.3 ng/mL). Five months later two neck lymph node
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Figure 2 Trend of serum onT4-Tg in two patients with recurrent DTC during long-term follow-up.
The dashed line represents the functional sensitivity of the assay.
metastases (6 and 8 mm) were detected by US with
a corresponding onT4-Tg increase to 0.9 ng/mL. The
second patient showed an increase in onT4-Tg
(0.4 ng/mL) 15 months following thyroid ablation.
Seven months later, neck US revealed an 11 mm
lymph node recurrence with a corresponding onT4-
Tg of 1.3 ng/mL. Recurring tumors were resected, and
in both cases Tg became undetectable (even after
rhTSH stimulation) with negative follow-up at 3.4 and
2.9 years, respectively (Figure 2). Finally, a progres-
sive increase in onT4-Tg from -0.2 ng/mL to 1.3
ng/mL in a 32-month period was observed in a patient
(0.5%) with negative results in multiple imaging pro-
cedures (i.e., biochemical recurrence). None of the
remaining 185 patients (98.5%) showed recurrence
over 6.8 (4.7–8.8) years of follow-up. Twelve of these
(6.4%) exhibited a slight increase in serum onT4-Tg
(ranging from 0.2 ng/mL to 0.6 ng/mL) that sponta-
neously fell to undetectable levels within 3–6 months
(i.e., negative Tg-trend).
Discussion
European and American Thyroid Association Guide-
lines suggest that a patient with DTC can be consid-
ered free of disease when there is no clinical evidence
of tumor, no imaging evidence of tumor and the
serum Tg is undetectable during TSH suppression
therapy and following TSH stimulation (1, 2). How-
ever, some authors found a negligible role for TSH
stimulation in a large number of patients having DTC,
primarily those with a low-risk profile (4–6, 11, 12).
Accordingly, we selected DTC patients with a low-risk
profile according to the European Thyroid Association
Guidelines, and evaluated the impact of serum onT4-
Tg measurement in both early and long-term out-
come while TSH stimulation was omitted. Six months
following thyroid ablation, an increase in serum onT4-
Tg occurred in four and three patients with (ns4) and
without (ns191) proven DTC recurrence, respectively
(sensitivity 100%, specificity 98%, positive predictive
value 98%, negative predictive value 100%, accuracy
98%). Our data agree with those of Schlumberger and
co-workers who showed that Tg immunoassays, with
a functional sensitivity of 0.2–0.3 ng/mL (comprising
the assay employed in our study), are accurate
enough to rule out TSH stimulation in the first follow-
up visit of 944 patients with DTC (13). Here, we also
show that false positive results were always associ-
ated with a spontaneous decrease within 3–6 months,
proving that a negative Tg trend has 100% negative
predictive value. Three of 188 patients negative
during early follow-up showed recurrence with a pro-
gressive increase of onT4-Tg in all cases. These
results agree with data from Zophel and co-workers
who studied 126 patients with radically cured disease
over a 4-year period. The Tg levels increased in five
(4%) patients; proven recurrence was seen in four
patients while the fifth remained well, despite rising
serum Tg concentrations that could be stimulated by
TSH (14). Finally, a transient increase in onT4-Tg
occurred in 12 disease-free patients during long-term
follow-up. However, the marker spontaneously
declined within 3–6 months in all cases. As a result,
monitoring the onT4-Tg trend allowed us to accurate-
ly discriminate between patients with recurrence of
DTC from those without recurrences.
Limitations
DTC recurrence can occur decades following thyroid
ablation. Consequently, life-long monitoring is
required. In this respect, the follow-up period needs
to be longer for our patients, and our data should be
regarded as preliminary. However, most recurrent or
persistent tumor is detected during the first 5 years
following thyroidectomy (15). Our patients will be
monitored further in order to evaluate overall survival
and cancer related morbidity over a longer period.
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Conclusions
Undetectable serum onT4-Tg with a high-sensitive
immunoradiometric assay following thyroid ablation
predicts low-risk of DTC recurrence. When onT4-Tg
became detectable during follow-up, the evaluation of
the Tg-slope in a 3–6 month period accurately dis-
criminated between patients recurrence of DTC from
those without recurrence. This helps to avoid unnec-
essary diagnostic or therapeutic procedures.
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